# Magnet Biomedicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/magnet-biomedicine

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.magnetbio.com
- Total disclosed funding: $50M
- Latest round: Series A (Sep 19, 2023)
- Investors on record: 2

## About

Based in Massachusetts, US, Magnet Biomedicine, Inc. operates as a research and development company for molecular glue medicines for the treatment of cancer, cardiovascular disease, and immune disorders. The company was co-founded by David Spiegel, Michael Rosbash, Richa Saxena, and Stuart Schreiber. In September 2023, Magnet Biomedicine, Inc. raised USD 50 million in Series A funding co-led by new investors Newpath Partners and ARCH Venture Partners. 

The company's platform discovers genuine molecular glues, offering exciting prospects for treating human diseases. Leveraging advancements in human biology and proteomics, the company’s platform identifies glues tailored for specific purposes for treatment purposes. These glues provide benefits such as improved targeting, synergistic effects on specific targets, and the ability to address historically challenging proteins. The company engages in combating various diseases and biological mechanisms, including cancer, cardiovascular issues, and immune disorders.

## Funding rounds

- Series A, Sep 19, 2023, $50M — ARCH Venture Partners, Newpath Partners

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Newpath Partners (https://capitalatlas.ai/funds/newpath-partners) — Series A